<p>Analysis of a patient biopsy from the clinical trial (<a href="https://clinicaltrials.gov/ct2/results?term=NCT03240861">NCT03240861</a>), a first-in-human study of transgenic NY-ESO-1 TCR- T cells and NY-ESO-1 TCR+ sr39tk autologous hematopoietic stem cells tandem therapy for solid tumors after myeloablative conditioning chemotherapy with busulfan and fludarabine. Single-cell RNAseq and single-cell ATACseq analysis from peripheral blood mononuclear cells obtained from subject NYSCT-03.</p>

Human Cancer-Targeted Immunity via Transgenic Hematopoietic Stem Cell    Progeny

Sarcoma, Synovial study with ATAC-seq, RNA-Seq data on dbGaP (1 participants)

Human Cancer-Targeted Immunity via Transgenic Hematopoietic Stem Cell Progeny

Description

Applying For Access

Summary